An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study

Gastrointestinal Cancer

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Int J Cancer

Potthoff K, Uhlig J, Jacobasch L, Müller L, Reiser M, de Buhr R, Polata S, Gerger A, Zehrer V, Amann A, Göhler T, Serrer L, Schröder J, Semsek D, Köhler A, Stübs P, Prager G, Siebenbach HU, Schuch A, Marschner N

doi: 10.1002/ijc.70139

Gastrointestinal Cancer

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Int J Cancer

van Nassau SCMW, Zwart K, van der Baan FH, Vink GR, Elferink MAG, Snaebjornsson P, May AM, Koopman M, Roodhart JML

doi: 10.1002/ijc.35410

Gastrointestinal Cancer

Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial

Eur J Cancer

Michiel Zeeuw J, Kemna R, Ali M, van Eck S, Wesdorp NJ, Roor J, van Waesberghe JHTM, van den Bergh JE, Nota IMGC, Moos SI, van Dieren S, van Amerongen MJ, Bond MJG, Chapelle T, van Dam RM, Engelbrecht MRW, Gerhards MF, Grunhagen DJ, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Quintus Molenaar I, Patijn GA, Rijken AM, Ruers TM, Verhoef C, de Wilt JHW, Buffart TE, Swijnenburg RJ, Punt CJA, Verpalen IM, Stoker J, Huiskens J, Kazemier G, CAIRO5 research group

doi: 10.1016/j.ejca.2025.115738

Genitourinary Cancer

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Prostate

Shimomura T, Otsuka N, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group

doi: 10.1002/pros.24885

Gastrointestinal Cancer

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial

Eur J Cancer

Taieb J, Modest DP, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Gravalos C, Bragagnoli AC, Barboux V, Roby L, Amellal N, Prager GW

doi: 10.1016/j.ejca.2025.115644

Gastrointestinal Cancer

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

J Clin Oncol

Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Tran Q, Cremolini C, Fakih M

doi: 10.1200/JCO-24-02026

Gastrointestinal Cancer

Gravida and birth outcomes prior to and after diagnosis of early age onset colorectal cancer among female patients: Population-based epidemiologic studies

Cancer Epidemiol Biomarkers Prev

Oveisi N, Sayre EC, Gill S, Cheng V, Cheng V, Brotto LA, Peacock S, McTaggart-Cowan H, Hanley GE, Srikanthan A, De Vera MA

doi: 10.1158/1055-9965.EPI-25-0442

Breast Cancer

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Int J Cancer

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown J, Pienkowski T, Bee V, Casas M, Polonio Ó, Bezares S, Slamon D

doi: 10.1002/ijc.35432

Breast Cancer

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group

Lancet Oncol

Jensen MB, Torpe E, Teunissen Z, Taarnhøj G, Brix E, Knoop A, Yammeni S, Donskov F, Ejlertsen B

doi: 10.1016/S1470-2045(25)00085-3

Related content

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort

Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer

Gravida and birth outcomes prior to and after diagnosis of early age onset colorectal cancer among female patients: Population-based epidemiologic studies

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group